Claims
- 1. A method for treating a skin or hair disorder on a mammalian organism in need of such treatment, comprising administering to such organism a cosmetically/therapeutically effective amount of a cosmetic/therapeutic composition comprising a cosmetically or therapeutically effective amount of an adamantyl-substituted polycyclic acetylene compound having the structural formula (I) an adamantyl-substituted polycyclic acetylene compound having the structural formula (I): ##STR7## in which X represents a hydrogen atom or a halogen atom; R.sub.1 represents a hydrogen atom, a --CH.sub.3 radical, a --CH.sub.2 --O--R.sub.4 radical, a --CH.sub.2 --O--CO--R.sub.5 radical, an --O--R.sub.6 radical, an --O--(CH.sub.2).sub.m --(CO).sub.n --R.sub.7 radical, a --(CH.sub.2).sub.p --CO--R.sub.8 radical, a --(CH.sub.2).sub.p --CO--O--R.sub.9 radical or an --S(O).sub.p --R.sub.10 radical, wherein the m, n and p and the radicals R.sub.4 to R.sub.10 are defined below; Ar is a radical selected from among those of the following radicals of formulae (a)-(f): ##STR8## wherein R.sub.10 and R.sub.11 are as defined below; R.sub.2 is a hydrogen atom or a halogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms, an --O--CH.sub.2 --O--CH.sub.2 --CH.sub.2 --O--CH.sub.3 radical or an --O--R.sub.13 radical, wherein R.sub.13 is as defined below; R.sub.3 is an --O--CH.sub.2 --O--CH.sub.2 --CH.sub.2 --O--CH.sub.3 radical, a --(Y).sub.n --(CH.sub.2).sub.q --R.sub.14 radical, a --(CH.sub.2).sub.m --Y--(CH.sub.2).sub.q --R.sub.14 radical or a --CH.dbd.CH--(CH.sub.2).sub.t --R.sub.14, radical, wherein m, n, q and t and the Y and R.sub.14 radicals are as defined below; m, is an integer equal to 1, 2 or 3, n, is an integer equal to 0 or 1, p is an integer equal to 0, 1, 2 or 3, q is an integer ranging from 0 and 12, inclusive, and t is an integer ranging from 0 to 10, inclusive, R.sub.4 is a hydrogen atom or a lower alkyl radical; R.sub.5 is a lower alkyl radical; R.sub.6 is a hydrogen atom or a lower alkyl radical; R.sub.7 is a lower alkyl radical or a radical: ##STR9## in which R' and R", identical or different, are each a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl radical or an amino acid or peptide or sugar residue, with the proviso that R' and R" may together form, with the nitrogen atom from which they depend, a nitrogen-containing heterocycle; R.sub.9 is a hydrogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms, an alkenyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl or aralkyl radical, or a sugar residue or an amino acid or peptide residue, R.sub.10 is a hydrogen atom or a lower alkyl radical; R.sub.11 is a hydrogen atom, a halogen atom, a lower alkyl radical, a hydroxyl radical, or an --O--R.sub.12 or --O--COR.sub.12 radical, R.sub.12 is as defined below; R.sub.12 is as a lower alkyl radical; R.sub.13 is a hydrogen atom or a linear or branched alkyl radical having from 1 to 20 carbon atoms; R.sub.14 is a hydrogen atom, a lower alkyl radical, an alkenyl radical, an alkynyl radical, a C.sub.3 -C.sub.6 cycloaliphatic radical, a mono- or polyhydroxyalkyl radical, said hydroxyls are optionally being protected as methoxy, acetoxy or acetonide groups, an aryl or aralkyl radical, a --CO--R.sub.8 radical, a --COOR.sub.9 radical, an --S(O).sub.p --R.sub.10 radical, a radical: ##STR10## or, but only in the event that n is equal to 0 and R.sub.3 is .sub.-- (Y).sub.n-- (CH.sub.2).sub.q-- R.sub.14, a hydroxyl radical, an --O--R.sub.12 radical or an --O--COR.sub.12 radical, Y is an oxygen or sulphur atom or an --S(O).sub.p radical; or a pharmaceutically/cosmetically acceptable salt or optical or geometric isomer thereof.
- 2. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of Formula (I), Ar has the structure (a).
- 3. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of Formula (I), Ar has the structure (b).
- 4. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of Formula (I), Ar has the structure (c).
- 5. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of Formula (I), Ar has the structure (d).
- 6. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of Formula (I), Ar has the structure (e).
- 7. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of Formula (I), Ar has the structure (f).
- 8. The method of claim 1, wherein said adamantyl-substituted polycyclic acetylene compound comprises a pharmaceutically acceptable salt of the compound having structural formula (I).
- 9. The method of claim 1, where in said adamantyl-substituted polycyclic acetylene compound of Formula (I), the lower alkyl substituents are selected from the group consisting of methyl, ethyl, isopropyl, butyl, tert.-butyl and hexyl radicals.
- 10. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the linear or branched alkyl radical substituents having from 1 to 20 carbon atoms are selected from the group consisting of methyl, ethyl, propyl, 2-ethylhexyl, octyl, dodecyl, hexadecyl and octadecyl radicals.
- 11. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the monohydroxyalkyl radical substituents are selected from the group consisting of 2-hydroxypropyl and 3-hydroxypropyl radicals.
- 12. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the polyhydroxyalkyl radical substituents are selected from the group consisting of 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl, 2,3,4,5-tetrahydroxypentyl and pentaerythritol radicals.
- 13. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the aryl radical substituents are selected from the group consisting of phenyl radicals optionally substituted by at least one halogen atom, a hydroxyl and a nitro functional group.
- 14. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the aralkyl radical substituents are selected from the group consisting of benzyl and phenethyl radicals optionally substituted by at least one halogen atom, or a hydroxyl or nitro functional group.
- 15. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the alkenyl radical substituents have from 2 to 5 carbon atoms and have at least one site of ethylenic unsaturation.
- 16. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the alkynyl radical substituents have from 2 to 6 carbon atoms.
- 17. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the sugar residue substituents are selected from the group consisting of glucose, galactose, mannose and glucuronic acid.
- 18. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the amino acid residue substituents are selected from the group consisting of lysine, glycine and aspartic acid.
- 19. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the peptide residue substituents are those of a dipeptide or tripeptide.
- 20. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the heterocyclic radical substituents are selected from the group consisting of piperidino, morpholino, pyrrolidino and piperazino radicals which are optionally substituted by a C.sub.1 -C.sub.6 alkyl radical or a mono- or polyhydroxyalkyl radical.
- 21. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), the halogen atom substituents are selected from the group consisting of fluorine, chlorine and bromine atoms.
- 22. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound is selected from the group consisting of
- 4-�3-(1-Adamantyl)-4-methoxyphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-methoxyethoxymethoxyphenylethynyl!-benzoic acid
- 4-�3-(1-Adamantyl)-4-hydroxyphenylethynyl!benzoic acid
- 5-�3-(1-Adamantyl)-4-methoxyphenylethynyl!-2-thiophenecarboxylic acid
- 5-�3-(1-Adamantyl)-4-hydroxyphenylethynyl!-2-thiophenecarboxylic acid
- 2-�3-(1-Adamantyl)-4-methoxyphenylethynyl!-4-thiophenecarboxylic acid
- 6-�3-(1-Adamantyl)-4-methoxyphenylethynyl!-2-naphthoic acid
- 4-�3-(1-Adamantyl)-4-nonyloxyphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-hexyloxyphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-dodecyloxyphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-cyclopropylmethoxyphenylethynyl!benzoic acid
- 4-�2-Hexyloxy-5-(1-adamantyl)-4-hexyloxyphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-heptyloxyphenylethynyl!benzoic acid
- 6-�3-(1-Adamantyl)-4-methoxyethoxymethoxyphenylethynyl!-nicotinic acid
- 4-�2-Methoxy-5-(1-adamantyl)-4-methoxyphenylethynyl!benzoic acid
- 4-�2-Methoxyethoxymethoxy-5-(1-adamantyl)-4-methoxyethoxymethoxyphenylethynyl!benzoic acid
- 4-�2-Methoxy-5-(1-adamantyl)-4-methoxyethoxymethoxyphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-benzyloxyphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-methoxyethoxymethoxyphenylethynyl!-benzaldehyde
- 4-�3-(1-Adamantyl)-4-methoxyethoxymethoxyphenylethynyl!-benzenemethanol
- 4-�3-(1-Adamantyl)-4-methoxyethoxymethoxyphenylethynyl!-benzyl acetate
- 4-�3-(1-Adamantyl)-4-methoxyethoxymethoxyphenylethynyl!-phenyl acetate
- 4-�3-(1-Adamantyl)-4-methoxyethoxymethoxyphenylethynyl!-phenol
- 4-�3-(1-Adamantyl)-4-methoxyethoxymethoxyphenylethynyl!-phenoxyethylmorpho-line
- 4-�3-(1-Adamantyl)-4-methoxyethoxymethoxyphenylethynyl!benzamide
- N-Ethyl-4-�3-(1-adamantyl)-4-methoxyethoxymethoxyphenylethynyl!benzamide
- 4-�3-(1-Adamantyl)-4-methoxyethoxymethoxyphenylethynyl!benzoic acid morpholide
- 2-Hydroxy-4-�3-(1-adamantyl)-4-methoxyethoxymethoxyphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-(6-hydroxyhexyloxy)phenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-(6-methoxyhexyloxy)phenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-�2-(4-morpholino)-ethoxy!phenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-(6-carbamoylpropyloxy)phenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-(5-carbamoylpentyloxy)phenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-(3-hydroxypropyloxy)phenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-(3-hydroxy-2-methylpropyloxy)phenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-�(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy!phenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-(2,3-dihydroxypropyloxy)phenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-methoxyethoxyethylphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-methoxymethoxypropylphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-methoxyethoxypropylphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-acetoxybutoxyphenylethynyl!benzoic acid
- 4-�3-(1-Adamantyl)-4-acetoxypropyloxyphenylethynyl!benzoic acid.
- 23. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound is an alkali or alkaline earth metal, zinc or amine salt.
- 24. The method of claim 1, where in the adamantyl-substituted polycyclic acetylene compound of formula (I), at least one R.sub.1, R.sub.2, R.sub.3 or Ar must be defined as set forth below:
- R.sub.1 is a --(CH.sub.2).sub.p --CO--R.sub.8 radical;
- R.sub.3 is an --O--CH.sub.2 --O--CH.sub.2 --CH.sub.2 --O--CH.sub.3 or ----(--Y--)----.sub.n ----(--CH.sub.2 --)----.sub.q --R.sub.14 radical;
- Ar is a radical selected from among those of formulae (a) and (e); and
- R.sub.2 is a linear or branched alkyl radical having from 1 to 20 carbon atoms or an --O--R.sub.13 radical.
Priority Claims (1)
Number |
Date |
Country |
Kind |
94 05018 |
Apr 1994 |
FRX |
|
CROSS-REFERENCE TO COMPANION APPLICATIONS
This application is a divisional of application Ser. No. 08/429,045, filed Apr. 26, 1995, now U.S. Pat. No. 5,574,036. Copending applications Ser. No. 08/429,096, �Attorney Docket No. 016800-023! and Ser. No. 08/429,492 �Attorney Docket No. 016800-024!, both filed concurrently herewith and assigned to the assignee hereof. Cf. copending applications Ser. No. 08/350,913 �Attorney Docket No. 016800-006!, Ser. No. 08/357,024 �Attorney Docket No. 016800-007! and Ser. No. 08/356,680 �Attorney Docket No. 016800-008!, each filed Dec. 15, 1994 and each also assigned to the assignee hereof.
Foreign Referenced Citations (1)
Number |
Date |
Country |
0176034 |
Apr 1986 |
EPX |
Non-Patent Literature Citations (1)
Entry |
Chemical Abstracts, vol. 87, No. 3, Jul. 18, 1977, Columbus, Ohio; abstract No. 22693b, Musantaeva, Sh. et al, "Synthesis of P-Acetylenylbenzoic Acid", p. 599, Col. 2; & Deposited Doc., 1974, pp. 297-375, VINTI. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
429045 |
Apr 1995 |
|